Back to video list Back to Home If optimizing the dose of the current antidepressant is not an effective strategy, at which part of the dose range can we consider adding an augmenting agent? You may also like Parkinson's Disease Article Biomarkers – ever closer in PD Depression Bipolar Article Inflammatory biomarkers in mood disorders and implications for treatment Alzheimer's Disease Article High Mobility Group Box 1 (HMGB1) in Vascular Dementia: Mechanism, Biomarker Potential, and Therapeutic Implication Alzheimer's Disease Article Addressing challenges of dosage and administration in the development of disease-modifying therapy